166 related articles for article (PubMed ID: 32884960)
1. Directed Blocking of TGF-β Receptor I Binding Site Using Tailored Peptide Segments to Inhibit its Signaling Pathway.
Sepehri S; Arab SS; Behmanesh M; H Sajedi R
Iran J Biotechnol; 2020 Jan; 18(1):e2561. PubMed ID: 32884960
[TBL] [Abstract][Full Text] [Related]
2. Peptide ligands that use a novel binding site to target both TGF-β receptors.
Li L; Orner BP; Huang T; Hinck AP; Kiessling LL
Mol Biosyst; 2010 Dec; 6(12):2392-402. PubMed ID: 20890540
[TBL] [Abstract][Full Text] [Related]
3. A pivotal role for the transmembrane domain in transforming growth factor-beta receptor activation.
Zhu HJ; Sizeland AM
J Biol Chem; 1999 Apr; 274(17):11773-81. PubMed ID: 10206994
[TBL] [Abstract][Full Text] [Related]
4. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily.
Radaev S; Zou Z; Huang T; Lafer EM; Hinck AP; Sun PD
J Biol Chem; 2010 May; 285(19):14806-14. PubMed ID: 20207738
[TBL] [Abstract][Full Text] [Related]
5. TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling.
Tazat K; Hector-Greene M; Blobe GC; Henis YI
Mol Biol Cell; 2015 Oct; 26(19):3535-45. PubMed ID: 26269580
[TBL] [Abstract][Full Text] [Related]
6. Binding Properties of the Transforming Growth Factor-β Coreceptor Betaglycan: Proposed Mechanism for Potentiation of Receptor Complex Assembly and Signaling.
Villarreal MM; Kim SK; Barron L; Kodali R; Baardsnes J; Hinck CS; Krzysiak TC; Henen MA; Pakhomova O; Mendoza V; O'Connor-McCourt MD; Lafer EM; López-Casillas F; Hinck AP
Biochemistry; 2016 Dec; 55(49):6880-6896. PubMed ID: 27951653
[TBL] [Abstract][Full Text] [Related]
7. Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent.
Zúñiga JE; Groppe JC; Cui Y; Hinck CS; Contreras-Shannon V; Pakhomova ON; Yang J; Tang Y; Mendoza V; López-Casillas F; Sun L; Hinck AP
J Mol Biol; 2005 Dec; 354(5):1052-68. PubMed ID: 16289576
[TBL] [Abstract][Full Text] [Related]
8. Targeting all transforming growth factor-β isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer.
Takahashi K; Akatsu Y; Podyma-Inoue KA; Matsumoto T; Takahashi H; Yoshimatsu Y; Koinuma D; Shirouzu M; Miyazono K; Watabe T
J Biol Chem; 2020 Sep; 295(36):12559-12572. PubMed ID: 32631954
[TBL] [Abstract][Full Text] [Related]
9. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II.
Guerrero-Esteo M; Sanchez-Elsner T; Letamendia A; Bernabeu C
J Biol Chem; 2002 Aug; 277(32):29197-209. PubMed ID: 12015308
[TBL] [Abstract][Full Text] [Related]
10. Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction.
Luo K; Lodish HF
EMBO J; 1996 Sep; 15(17):4485-96. PubMed ID: 8887540
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I/Type II receptor complex in live cells.
Wells RG; Gilboa L; Sun Y; Liu X; Henis YI; Lodish HF
J Biol Chem; 1999 Feb; 274(9):5716-22. PubMed ID: 10026191
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta (TGF-beta) type I and type II receptors are both required for TGF-beta-mediated extracellular matrix production in lung fibroblasts.
Zhao Y
Mol Cell Endocrinol; 1999 Apr; 150(1-2):91-7. PubMed ID: 10411303
[TBL] [Abstract][Full Text] [Related]
13. TGM6, a helminth secretory product, mimics TGF-β binding to TβRII to antagonize TGF-β signaling in fibroblasts.
White SE; Schwartze TA; Mukundan A; Schoenherr C; Singh SP; van Dinther M; Cunningham KT; White MPJ; Campion T; Pritchard J; Hinck CS; Ten Dijke P; Inman G; Maizels RM; Hinck AP
bioRxiv; 2023 Dec; ():. PubMed ID: 38187573
[TBL] [Abstract][Full Text] [Related]
14. Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule.
Qian SW; Burmester JK; Tsang ML; Weatherbee JA; Hinck AP; Ohlsen DJ; Sporn MB; Roberts AB
J Biol Chem; 1996 Nov; 271(48):30656-62. PubMed ID: 8940041
[TBL] [Abstract][Full Text] [Related]
15. Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors.
Rechtman MM; Nakaryakov A; Shapira KE; Ehrlich M; Henis YI
J Biol Chem; 2009 Mar; 284(12):7843-52. PubMed ID: 19147499
[TBL] [Abstract][Full Text] [Related]
16. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
Deng X; Bellis S; Yan Z; Friedman E
Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
[TBL] [Abstract][Full Text] [Related]
17. Single-molecule force spectroscopy study of interaction between transforming growth factor beta1 and its receptor in living cells.
Yu J; Wang Q; Shi X; Ma X; Yang H; Chen YG; Fang X
J Phys Chem B; 2007 Dec; 111(48):13619-25. PubMed ID: 17997544
[TBL] [Abstract][Full Text] [Related]
18. Natural velvet antler polypeptide conformation prediction and molecular docking study with TGF-β1 complex.
Shang YD; Zhang JL; Zheng QC
J Mol Model; 2013 Sep; 19(9):3671-82. PubMed ID: 23771398
[TBL] [Abstract][Full Text] [Related]
19. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2.
del Re E; Babitt JL; Pirani A; Schneyer AL; Lin HY
J Biol Chem; 2004 May; 279(21):22765-72. PubMed ID: 14996829
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
